190 related articles for article (PubMed ID: 23516601)
1. pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members.
Zhang YJ; Gallis B; Taya M; Wang S; Ho RJ; Sasaki T
PLoS One; 2013; 8(3):e59086. PubMed ID: 23516601
[TBL] [Abstract][Full Text] [Related]
2. Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines.
Gong Y; Gallis BM; Goodlett DR; Yang Y; Lu H; Lacoste E; Lai H; Sasaki T
Anticancer Res; 2013 Jan; 33(1):123-32. PubMed ID: 23267137
[TBL] [Abstract][Full Text] [Related]
3. pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model.
Zhang YJ; Zhan X; Wang L; Ho RJ; Sasaki T
J Pharm Sci; 2015 May; 104(5):1815-24. PubMed ID: 25753991
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Dual Bioactive Compounds Artemisinin and Metformin Co-loaded in PLGA-PEG Nano-particles on Breast Cancer Cell lines: Potential Apoptotic and Anti-proliferative Action.
Hassani N; Jafari-Gharabaghlou D; Dadashpour M; Zarghami N
Appl Biochem Biotechnol; 2022 Oct; 194(10):4930-4945. PubMed ID: 35674922
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of artemisinin dimers using the Ugi reaction and their in vitro efficacy on breast cancer cells.
Wang S; Sasaki T
Bioorg Med Chem Lett; 2013 Aug; 23(15):4424-7. PubMed ID: 23790541
[TBL] [Abstract][Full Text] [Related]
6. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
[TBL] [Abstract][Full Text] [Related]
7. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
8. An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities.
He R; Mott BT; Rosenthal AS; Genna DT; Posner GH; Arav-Boger R
PLoS One; 2011; 6(8):e24334. PubMed ID: 21904628
[TBL] [Abstract][Full Text] [Related]
9. Novel artemisinin derivatives with potent anticancer activities and the anti-colorectal cancer effect by the mitochondria-mediated pathway.
Lin L; Lu W; Dai T; Chen H; Wang T; Yang L; Yang X; Liu Y; Sun D
Bioorg Chem; 2021 Jan; 106():104496. PubMed ID: 33288320
[TBL] [Abstract][Full Text] [Related]
10. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells.
Morrissey C; Gallis B; Solazzi JW; Kim BJ; Gulati R; Vakar-Lopez F; Goodlett DR; Vessella RL; Sasaki T
Anticancer Drugs; 2010 Apr; 21(4):423-32. PubMed ID: 20130467
[TBL] [Abstract][Full Text] [Related]
11. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.
Kumari K; Keshari S; Sengupta D; Sabat SC; Mishra SK
BMC Cancer; 2017 Dec; 17(1):858. PubMed ID: 29246124
[TBL] [Abstract][Full Text] [Related]
13. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.
Brouxhon SM; Kyrkanides S; Teng X; O'Banion MK; Clarke R; Byers S; Ma L
Mol Carcinog; 2014 Nov; 53(11):893-906. PubMed ID: 23776059
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.
Buragohain P; Saikia B; Surineni N; Barua NC; Saxena AK; Suri N
Bioorg Med Chem Lett; 2014 Jan; 24(1):237-9. PubMed ID: 24332623
[TBL] [Abstract][Full Text] [Related]
15. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
16. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
17. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of anti-cancer agents that selectively inhibit Her2 over-expressed breast cancer cell growth via down-regulation of Her2 protein.
Zhao A; Zheng Q; Orahoske CM; Idippily ND; Ashcraft MM; Quamine A; Su B
Bioorg Med Chem Lett; 2018 Feb; 28(4):727-731. PubMed ID: 29352646
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
20. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity.
Shrivastava R; Trivedi S; Singh PK; Asif M; Chourasia MK; Khanna A; Bhadauria S
Biochem Biophys Res Commun; 2018 Sep; 503(2):677-683. PubMed ID: 29908185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
